• Monte Rosa Therapeutics President and CEO Markus Warmuth sold 9,500 common shares on July 16, 2026.
• Shares were sold at a weighted average price of $23.18.
• Warmuth held 585,038 shares following the transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-307791), on July 17, 2026, and is solely responsible for the information contained therein.